MX2019009630A - Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion. - Google Patents

Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.

Info

Publication number
MX2019009630A
MX2019009630A MX2019009630A MX2019009630A MX2019009630A MX 2019009630 A MX2019009630 A MX 2019009630A MX 2019009630 A MX2019009630 A MX 2019009630A MX 2019009630 A MX2019009630 A MX 2019009630A MX 2019009630 A MX2019009630 A MX 2019009630A
Authority
MX
Mexico
Prior art keywords
combination
wnt inhibitor
antibody molecule
dosing schedule
inhibitor
Prior art date
Application number
MX2019009630A
Other languages
English (en)
Inventor
Russell DOBSON Jason
MOODY Susan
Elise MCLAUGHLIN Margaret
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019009630A publication Critical patent/MX2019009630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se refiere al campo de la farmacia, particularmente a un inhibidor de Wnt y un inhibidor de PD-1 para uso en el tratamiento del cáncer. Específicamente, la descripción se refiere a una combinación farmacéutica que comprende un inhibidor de Wnt, o una sal farmacéuticamente aceptable del mismo, y un inhibidor de PD-1, o una sal farmacéuticamente aceptable del mismo, para usar en el tratamiento del cáncer, a un método para el tratamiento de cáncer que implica administrar la combinación y el uso de la combinación para la fabricación de un medicamento para el tratamiento del cáncer.
MX2019009630A 2017-02-14 2018-02-12 Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion. MX2019009630A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US201862616682P 2018-01-12 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Publications (1)

Publication Number Publication Date
MX2019009630A true MX2019009630A (es) 2019-11-08

Family

ID=61526841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009630A MX2019009630A (es) 2017-02-14 2018-02-12 Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.

Country Status (12)

Country Link
US (2) US11406633B2 (es)
EP (1) EP3582811A1 (es)
JP (2) JP2020506159A (es)
KR (2) KR20190112801A (es)
CN (2) CN117752784A (es)
AU (1) AU2018221557C1 (es)
CA (1) CA3051989A1 (es)
IL (1) IL268341B2 (es)
MX (1) MX2019009630A (es)
RU (1) RU2767533C2 (es)
TW (1) TWI771372B (es)
WO (1) WO2018150312A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
CA3007671A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20210395351A1 (en) 2018-09-27 2021-12-23 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
EP3972607A4 (en) * 2019-05-22 2023-08-16 Agency for Science, Technology and Research PHARMACEUTICAL COMBINATION
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆
CN107613980A (zh) * 2015-05-31 2018-01-19 源生公司 用于免疫疗法的组合组合物

Also Published As

Publication number Publication date
JP2022174157A (ja) 2022-11-22
CA3051989A1 (en) 2018-08-23
RU2019128843A3 (es) 2021-05-17
CN110267682A (zh) 2019-09-20
WO2018150312A1 (en) 2018-08-23
US20190365746A1 (en) 2019-12-05
CN117752784A (zh) 2024-03-26
AU2018221557A1 (en) 2019-08-15
RU2767533C2 (ru) 2022-03-17
RU2019128843A (ru) 2021-03-16
AU2018221557B2 (en) 2021-03-11
KR20240007717A (ko) 2024-01-16
AU2018221557C1 (en) 2021-10-14
TWI771372B (zh) 2022-07-21
IL268341A (en) 2019-09-26
IL268341B2 (en) 2023-06-01
EP3582811A1 (en) 2019-12-25
KR20190112801A (ko) 2019-10-07
US20230063366A1 (en) 2023-03-02
US11406633B2 (en) 2022-08-09
TW201836610A (zh) 2018-10-16
JP2020506159A (ja) 2020-02-27

Similar Documents

Publication Publication Date Title
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
EP4279087A3 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2016008362A (es) Combinaciones farmaceuticas.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
AU2018256669A1 (en) Combination therapy
MX356704B (es) Combinación.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX362533B (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.